Amendments t the claims

1. (currently amended) A compound of Formula (I):



(I)

or a stereoisomer, or pharmaceutically acceptable salt form ~~or prodrug~~ thereof, wherein:

A^1 is C_1-C_3 alkylene substituted by 0-2 C_1-C_4 alkyl;

A^2 is ~~$-C(=O)R^{9b}$, $-S(=O)R^{9b}$, $-S(=O)_2R^{9b}$, $-CONHR^{9b}$,~~

~~$-S(=O)_2NHR^{9b}$, $-C(=O)OR^{9b}$,~~

$-A^3-R^{9a}$;

~~$-A^3-A^4-R^{9a}$,~~

~~$-A^3-A^4-A^5-R^{9a}$; or~~

~~$-A^3-A^4-A^5-A^6-R^{9a}$,~~

W is ~~selected from the group:~~

$-B(OR^{26})(OR^{27})$,

~~$-C(=O)C(=O)-Q$,~~

~~$-C(=O)C(=O)NH-Q$,~~

~~$-C(=O)C(=O)-O-Q$,~~

~~$-C(=O)CF_2C(=O)NH-Q$,~~

~~$-C(=O)CF_3$,~~

~~$-C(=O)CF_2CF_3$,~~

~~$-C(=O)H$, and~~

~~$-C(=O)W^1$~~;

W^1 is OR^8 or $NR^{11}R^{11a}$;

Q is selected from the group:

$-(CR^{10}R^{10c})_m-Q^1$,

$-(CR^{10}R^{10c})_m-Q^2$,

C_1-C_4-alkyl substituted with Q^1,

C_2-C_4-alkenyl substituted with Q^1,

C_2-C_4-alkynyl substituted with Q^1,

an amino acid residue,

A^7-A^8, and

A^7-A^8-A^9;

m is 1, 2, 3, or 4;

Q^1 is selected from the group:

CO_2R^{11}, SO_2R^{11}, SO_3R^{11}, $P(O)_2R^{11}$, $P(O)_3R^{11}$;

aryl substituted with 0-4 Q^{1a}; and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4 Q^{1a};

Q^{1a} is H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, CO_2R^{19}, $C(=O)NR^{19}R^{19a}$, $NHC(=O)R^{19}$, SO_2R^{19}, $SO_2NR^{19}R^{19a}$, $NR^{19}R^{19a}$, OR^{19}, SR^{19}, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkyl, or C_1-C_4-haloalkoxy;

Q^2 is $X-NR^{12}-Z$, $-NR^{12}-Y-Z$, or $-X-NR^{12}-Y-Z$;

X is $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, or $-P(O)_3-$;

Y is $-C(=O)-$, $-S-$, $-S(=O)-$, $-S(=O)_2-$, $-P(O)-$, $-P(O)_2-$, or $-P(O)_3-$;

Z is selected from the group:

C_1-C_4 haloalkyl;

C_1-C_4 alkyl substituted with 0-3 Z^a;

C_2-C_4 alkenyl substituted with 0-3 Z^a;

C_2-C_4 alkynyl substituted with 0-3 Z^a;

C_3-C_{10} cycloalkyl substituted with 0-5 Z^b;

aryl substituted with 0-5 Z^b;

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 Z^b;

an amino acid residue;

$-A^7-A^8-$, and

$-A^7-A^8-A^9-$;

Z^a is selected from the group:

H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3,

$-CO_2R^{20}$, $-C(=O)NR^{20}R^{20a}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20a}$,

~~$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20a}$, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-haloalkoxy;~~

~~C_3-C_{10}-cycloalkyl substituted with 0-5 Z^b;~~

~~C_3-C_{10}-carbocyle substituted with 0-5 Z^b;~~

~~aryl substituted with 0-5 Z^b; and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 Z^b;~~

~~Z^b is selected from the group:~~

~~H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20a}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20a}$, $-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20a}$, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-haloalkoxy;~~

~~C_3-C_{10}-cycloalkyl substituted with 0-5 Z^e;~~

~~C_3-C_{10}-carbocyle substituted with 0-5 Z^e;~~

~~aryl substituted with 0-5 Z^e; and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 Z^e;~~

~~Z^e is H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, $-CO_2R^{20}$, $-C(=O)NR^{20}R^{20a}$, $-NHC(=O)R^{20}$, $-NR^{20}R^{20a}$,~~

~~$-OR^{20}$, $-SR^{20}$, $-S(=O)R^{20}$, $-SO_2R^{20}$, $-SO_2NR^{20}R^{20a}$, C_1-C_4-alkyl, C_1-C_4-haloalkyl, or C_1-C_4-haloalkoxy;~~

R^1 is selected from the group: H, F;

C_1-C_6 alkyl substituted with 0-3 R^{1a};

C_2-C_6 alkenyl substituted with 0-3 R^{1a};

C_2-C_6 alkynyl substituted with 0-3 R^{1a}; and

C_3-C_6 cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:

Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, ~~$-CO_2R^{1b}$, $-SO_2R^{1b}$, $-SO_3R^{1b}$, $-P(O)_2R^{1b}$, $-P(O)_3R^{1b}$, $-C(=O)NHR^{1b}$, $-NHC(=O)R^{1b}$, $-SO_2NHR^{1b}$, $-OR^{1b}$, $-SR^{1b}$, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, $-S(C_1$-C_6-alkyl);~~

~~C_1-C_4-alkyl substituted with 0-3 R^{1c};~~

~~aryl substituted with 0-5 R^{1c};~~

~~$-O(CH_2)_n$-aryl substituted with 0-5 R^{1c};~~

~~$-S(CH_2)_n$-aryl substituted with 0-5 R^{1c}; and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{1c};~~

~~n is 0, 1 or 2;~~

~~R^{1b} is H;~~

~~C_1-C_4 alkyl substituted with 0-3 R^{1e};~~

~~C_2-C_4 alkenyl substituted with 0-3 R^{1e};~~

~~C_2-C_4 alkynyl substituted with 0-3 R^{1e};~~

~~C_3-C_6 cycloalkyl substituted with 0-5 R^{1e};~~

~~aryl substituted with 0-5 R^{1e};~~

~~aryl C_1-C_4 alkyl substituted with 0-4 R^{1e}; or~~

~~5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 R^{1e};~~

~~R^{1e} is selected at each occurrence from the group:~~

~~C_1-C_4 alkyl, Cl, F, Br, I, OH, SH, CN, NO_2, OR^{1d}, $C(=O)OR^{1d}$, $NR^{1d}R^{1d}$, SO_2R^{1d}, SO_3R^{1d}, $C(=O)NHR^{1d}$, $NHC(=O)R^{1d}$, SO_2NHR^{1d}, CF_3, OCF_3, C_3-C_6 cycloalkyl, phenyl, and benzyl;~~

~~R^{1d} is selected at each occurrence from the group: H, C_1-C_4 alkyl, phenyl and benzyl;~~

R^2 is selected from the group: H, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_4 cycloalkyl, and C_3-C_4 cycloalkyl(C_1-C_4 alkyl)-;

~~alternatively, R^1 and R^2 can be combined to form a 4-7 membered cyclic group consisting of carbon atoms; substituted with 0-2 R^{14};~~

R^3 is selected from the group: R^4,

$-(CH_2)_p-NH-R^4$,

$-(CH_2)_p-NHC(=O)-R^4$,

$-(CH_2)_p-C(=O)NH-R^4$,

$-(CH_2)_p-C(=O)O-R^4$,

$-(CH_2)_p-C(=O)C(=O)-R^4$,

$-(CH_2)_p-C(=O)C(=O)NH-R^4$,

$-(CH_2)_p-NHC(=O)NH-R^4$,

$-(CH_2)_p-NHC(=O)NHC(=O)-R^4$,

$-(CH_2)_p-NHS(=O)_2-R^4$,

$-(CH_2)_p-S(=O)_2NH-R^4$,

$-(CH_2)_p-C(=O)-R^4$,

$-(CH_2)_p-O-R^4$, and

$-(CH_2)_p-S-R^4$;

p is 0, 1, or 2;

R^4 is selected from the group:

C_1-C_6 alkyl substituted with 0-3 R^{4a};

C_2-C_6 alkenyl substituted with 0-3 R^{4a};

C_2-C_6 alkynyl substituted with 0-3 R^{4a};

C_3-C_{10} cycloalkyl substituted with 0-4 R^{4b};

C_3-C_{10} carbocycle substituted with 0-4 R^{4b};

aryl substituted with 0-5 R^{4b}; and

aryl-C_1-C_4 alkyl substituted with 0-5 R^{4b}; ~~and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 R^{4b};~~

R^{4a} is, at each occurrence, independently selected from:

H, ~~F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H, $C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$, $NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$, $S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, $NHC(=NH)NHR^{11}$, $C(=NH)NHR^{11}$, $=NOR^{11}$, $NR^{11}C(=O)OR^{11a}$, $NR^{11}C(=O)NR^{11}R^{11a}$, $NR^{11}SO_2NR^{11}R^{11a}$, $NR^{11}SO_2R^{11a}$, $OP(O)(OR^{11})_2$,~~

C_1-C_4 alkyl substituted with 0-3 R^{4b};

C_2-C_4 alkenyl substituted with 0-3 R^{4b};

C_2-C_4 alkynyl substituted with 0-3 R^{4b};

C_3-C_7 cycloalkyl substituted with 0-4 R^{4c};

C_3-C_{10} carbocycle substituted with 0-4 R^{4c}; and

aryl substituted with 0-5 R^{4c}; ~~and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4c};~~

R^{4b} is, at each occurrence, independently selected from:

H, ~~F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H, $C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$, $NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$, $S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, $NHC(=NH)NHR^{11}$, $C(=NH)NHR^{11}$, $=NOR^{11}$, $NR^{11}C(=O)OR^{11a}$, $OC(=O)NR^{11}R^{11a}$, $NR^{11}C(=O)NR^{11}R^{11a}$, $NR^{11}SO_2NR^{11}R^{11a}$, $NR^{11}SO_2R^{11a}$, $OP(O)(OR^{11})_2$,~~

C_1-C_4 alkyl substituted with 0-3 R^{4c};

C_2-C_4 alkenyl substituted with 0-3 R^{4c};

C_2-C_4 alkynyl substituted with 0-3 R^{4c};

C_3-C_6 cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d}; ~~and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4d};~~

R^{4c} is, at each occurrence, independently selected from:

H, ~~F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H, $C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$, $NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$, $S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy;~~

C_1-C_4 alkyl substituted with 0-3 R^{4d};

C_2-C_4 alkenyl substituted with 0-3 R^{4d};

C_2-C_4 alkynyl substituted with 0-3 R^{4d};

C_3-C_6 cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d}; ~~and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4d};~~

R^{4d} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, $-NO_2$, -CN, -NCS, $-CF_3$, $-OCF_3$, =O, OH, ~~$-CO_2H$, $-CO_2R^{11}$, $-C(=O)NR^{11}R^{11a}$, $-NHC(=O)R^{11}$, $-NR^{11}R^{11a}$, $-OR^{11a}$, $-SR^{11a}$, $-C(=O)R^{11a}$, $-S(=O)R^{11a}$, $-SO_2R^{11}$, $-SO_2NR^{11}R^{11a}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, phenyl, and benzyl;~~

~~R^8 is H or C_1-C_4 alkyl;~~

R^{9a} is selected from the group: H, ~~$-S(=O)R^{9b}$, $-S(=O)_2R^{9b}$, $-S(=O)_2NHR^{9b}$,~~ $-C(=O)R^{9b}$, $-C(=O)OR^{9b}$, $-C(=O)NHR^{9b}$, $-C(=O)NHC(=O)R^{9b}$;

C_1-C_6 alkyl substituted with 0-3 R^{9c};

C_2-C_6 alkenyl substituted with 0-3 R^{9c};

C_2-C_6 alkynyl substituted with 0-3 R^{9c};

~~C_3-C_6 cycloalkyl substituted with 0-3 R^{9d};~~

~~C_3-C_{14} carbocycle substituted with 0-4 R^{9d};~~

~~aryl substituted with 0-5 R^{9d}; and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated;~~

~~and said 5-10-membered heterocyclic group is substituted with 0-4 R^{9d};~~

R^{9b} is selected from the group: H;

C_1-C_6 alkyl substituted with 0-3 R^{9c};

C_2-C_6 alkenyl substituted with 0-3 R^{9c};

C_2-C_6 alkynyl substituted with 0-3 R^{9c};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9d};

C_3-C_{14} carbocycle substituted with 0-4 R^{9d}; and

aryl substituted with 0-5 R^{9d}; ~~and~~

~~5-10-membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10-membered heterocyclic group is substituted with 0-4 R^{9d};~~

R^{9c} is selected from the group: ~~CF_3, OCF_3, Cl, F, Br, I, =O, OH, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, CN, NO_2;~~

C_1-C_6 alkyl substituted with 0-3 R^{9d};

C_2-C_6 alkenyl substituted with 0-3 R^{9d};

C_2-C_6 alkynyl substituted with 0-3 R^{9d};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9e};

C_3-C_{14} carbocycle substituted with 0-4 R^{9e}; and

aryl substituted with 0-5 R^{9e}; ~~and~~

~~5-10-membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated;~~

~~and said 5-10 membered heterocyclic group is substituted with 0-4 R^{9e};~~

R^{9d} is selected at each occurrence from the group:

~~CF_3, OCF_3, Cl, F, Br, I, =O, OH, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, CN, NO_2;~~

C_1-C_4 alkyl substituted with 0-3 R^{9e};

C_1-C_4 alkoxy substituted with 0-3 R^{9e};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9e}; and

aryl substituted with 0-5 R^{9e}; ~~and~~

~~5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4 R^{9e};~~

R^{9e} is selected at each occurrence from the group:

C_1-C_4 alkyl, C_1-C_4 alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, -CN, and NO_2;

~~R^{10} is selected from the group: CO_2R^{11}, $NR^{11}R^{11a}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};~~

~~R^{10a} is selected from the group: halo, NO_2, CN, CF_3, CO_2R^{11}, $NR^{11}R^{11a}$, OR^{11}, SR^{11}, $C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};~~

~~R^{10b} is selected from the group: CO_2H, NH_2, OH, SH, and $C(=NH)NH_2$;~~

~~R^{10c} is H or C_1-C_4 alkyl;~~

~~alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};~~

R^{11} and R^{11a} are, at each occurrence, independently selected from the group: H;

C_1-C_6 alkyl substituted with 0-3 R^{11b};

C_2-C_6 alkenyl substituted with 0-3 R^{11b};

C_2-C_6 alkynyl substituted with 0-3 R^{11b};

C_3-C_7 cycloalkyl substituted with 0-3 R^{11b};

aryl substituted with 0-3 R^{11b}; and

aryl(C_1-C_4 alkyl)- substituted with 0-3 R^{11b};

R^{11b} is OH, C_1-C_4 alkoxy, F, Cl, Br, I, NH_2, or -NH(C_1-C_4 alkyl);

~~R^{12} is H or C_1-C_4 alkyl;~~

~~R^{14} is C_1-C_4 alkyl or C_2-C_4 alkenyl;~~

~~R^{19} and R^{19a} are independently selected from the group: H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, and C_3-C_6 cycloalkyl(C_1-C_4 alkyl);~~

~~alternatively, $NR^{19}R^{19a}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;~~

~~R^{20} and R^{20a} are independently selected from the group: H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4-alkyl)-, C_3-C_6 cycloalkyl, and C_3-C_6-cycloalkyl(C_1-C_4-alkyl);~~

~~alternatively, $NR^{20}R^{20a}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;~~

OR^{26} and OR^{27} are independently selected from:

a) -OH,

b) ~~F,~~

~~c) $NR^{28}R^{29}$,~~

~~d)~~ C_1-C_8 alkoxy, and

when taken together, OR^{26} and OR^{27} form:

~~e)~~ a cyclic boronic ester where said cyclic boronic ester contains from 2 to 20 carbon atoms~~, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O~~; and

~~f) a cyclic boronic amide where said boronic amide contains from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O; or~~

~~g) a cyclic boronic amide ester where said boronic amide ester contains from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;~~

~~R^{28} and R^{29}, are independently selected from: H, C_1-C_4 alkyl, aryl(C_1-C_4 alkyl), and C_3-C_7 cycloalkyl;~~

~~A^3, A^4, A^5, A^6, A^7, A^8, and A^9 are independently selected from an amino acid residue; and~~

~~an amino acid residue, at each occurence, independently comprises a natural amino acid, a modified amino acid or an unnatural amino acid wherein said natural, modified or unnatural amino acid is of either D or L configuration.~~ is valine.

2. (currently amended) A compound of Claim 1, or a stereoisomer, or a pharmaceutically acceptable salt form ~~or prodrug~~ thereof, wherein:

A^1 is $-CH_2-$ ~~or $-CH_2CH_2-$~~;

~~A^2 is $-C(=O)R^{9b}$, $-S(=O)R^{9b}$, $-S(=O)_2R^{9b}$, $-CONHR^{9b}$,~~
~~$-S(=O)_2NHR^{9b}$, $-C(=O)OR^{9b}$,~~
~~$-A^3-R^{9a}$,~~
~~$-A^3-A^4-R^{9a}$,~~
~~$-A^3-A^4-A^5-R^{9a}$, or~~
~~$-A^3-A^4-A^5-A^6-R^{9a}$,~~

~~W is selected from the group:~~
~~$-B(OR^{26})(OR^{27})$,~~
~~$-C(=O)C(=O)-Q$,~~
~~$-C(=O)C(=O)NH-Q$,~~
~~$-C(=O)C(=O)-O-Q$,~~

~~$-C(=O)CF_2C(=O)NH-Q$,~~

~~$-C(=O)CF_3$,~~

~~$-C(=O)CF_2CF_3$,~~

~~$-C(=O)H$, and~~

~~$-C(=O)W^1$,~~

~~W^1 is OR^8 or $NR^{11}R^{11a}$,~~

~~Q is selected from the group:~~

~~$-(CR^{10}R^{10e})_m-Q^1$,~~

~~C_1-C_4 alkyl substituted with Q^1,~~

~~C_2-C_4 alkenyl substituted with Q^1, and~~

~~C_2-C_4 alkynyl substituted with Q^1,~~

~~m is 1 or 2;~~

~~Q^1 is selected from the group:~~

~~$-CO_2R^{11}$, $-SO_2R^{11}$, $-SO_3R^{11}$, $-P(O)_2R^{11}$, $-P(O)_3R^{11}$,~~

~~phenyl substituted with 0-4 Q^{1a}, and~~

~~5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4 Q^{1a},~~

~~Q^{1a} is H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3,~~

~~$-CO_2R^{19}$, $-C(=O)NR^{19}R^{19a}$, $-NHC(=O)R^{19}$, $-SO_2R^{19}$,~~

~~$-SO_2NR^{19}R^{19a}$, $-NR^{19}R^{19a}$, $-OR^{19}$, $-SR^{19}$, C_1-C_4 alkyl,~~

~~C_1-C_4-alkoxy, C_1-C_4-haloalkyl, or C_1-C_4-haloalkoxy;~~

R^1 is selected from the group: H, ~~F;~~

C_1-C_6 alkyl ~~substituted with 0-3 R^{1a}~~;

C_2-C_6 alkenyl ~~substituted with 0-3 R^{1a}~~; and

C_2-C_6 alkynyl ~~substituted with 0-3 R^{1a}; and~~

~~C_3-C_6-cycloalkyl substituted with 0-3 R^{1a};~~

~~R^{1a} is selected at each occurrence from the group:~~

~~Cl, F, Br, I, CF_3, CHF_2, OH, =O, SH, CO_2R^{1b}, SO_2R^{1b}, SO_3R^{1b}, $P(O)_2R^{1b}$, $P(O)_3R^{1b}$, $C(=O)NHR^{1b}$, $NHC(=O)R^{1b}$, SO_2NHR^{1b}, OR^{1b}, SR^{1b}, C_3-C_6-cycloalkyl, C_1-C_6 alkoxy, S-(C_1-C_6-alkyl);~~

~~C_1-C_4-alkyl substituted with 0-3 R^{1c};~~

~~aryl substituted with 0-5 R^{1c};~~

~~$O(CH_2)_n$-aryl substituted with 0-5 R^{1c};~~

~~$S(CH_2)_n$-aryl substituted with 0-5 R^{1c}; and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{1c};~~

~~n is 0, 1 or 2;~~

~~R^{1b} is H;~~

~~C_1-C_4-alkyl substituted with 0-3 R^{1c};~~

~~C_2-C_4-alkenyl substituted with 0-3 R^{1e},~~

~~C_2-C_4-alkynyl substituted with 0-3 R^{1e},~~

~~C_3-C_6-cycloalkyl substituted with 0-5 R^{1e},~~

~~aryl substituted with 0-5 R^{1e},~~

~~aryl-C_1-C_4-alkyl substituted with 0-4 R^{1e}; or~~

~~5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 R^{1e},~~

~~R^{1e} is selected at each occurrence from the group:~~

~~C_1-C_4-alkyl, Cl, F, Br, I, OH, SH, CN, NO_2, OR^{1d}, $C(=O)OR^{1d}$, $NR^{1d}R^{1d}$, SO_2R^{1d}, SO_3R^{1d}, $C(=O)NHR^{1d}$, $NHC(=O)R^{1d}$, SO_2NHR^{1d}, CF_3, OCF_3, C_3-C_6-cycloalkyl, phenyl, and benzyl;~~

~~R^{1d} is selected at each occurrence from the group: H, C_1-C_4-alkyl, phenyl and benzyl;~~

R^2 is ~~selected from the group: H, C_1-C_4-alkyl, C_2-C_4-alkenyl, C_2-C_4 alkynyl, C_3-C_4-cycloalkyl, and C_3-C_4-cycloalkyl(C_1-C_4-alkyl);~~

~~alternatively, R^1 and R^2 can be combined to form a 4-7 membered cyclic group consisting of carbon atoms; substituted with 0-2 R^{14},~~

R^3 is selected from the group: ~~R^4,~~

~~$-(CH_2)_p-NH-R^4$,~~

~~$-(CH_2)_p-NHC(=O)-R^4$,~~

~~$-(CH_2)_p-C(=O)NH-R^4$,~~

~~$-(CH_2)_p-C(=O)O-R^4$,~~

~~$-(CH_2)_p-C(=O)C(=O)-R^4$,~~

~~$-(CH_2)_p-C(=O)C(=O)NH-R^4$,~~

~~$-(CH_2)_p-NHC(=O)NH-R^4$,~~

~~$-(CH_2)_p-NHC(=O)NHC(=O)-R^4$,~~

~~$-(CH_2)_p-NHS(=O)_2-R^4$,~~

~~$-(CH_2)_p-S(=O)_2NH-R^4$,~~

~~$-(CH_2)_p-C(=O)-R^4$,~~

~~$-(CH_2)_p-O-R^4$, and~~

~~$-(CH_2)_p-S-R^4$;~~

C_1-C_6 alkyl substituted with phenyl,

C_1-C_6 alkenyl substituted with phenyl,

$-CH_2CONHPh$, and

(2-phenylquinolin-4-yl)methyl;

~~p is 0, 1, or 2;~~

~~R^4 is selected from the group:~~

~~C_1-C_6 alkyl substituted with 0-3 R^{4a},~~

~~C_2-C_6 alkenyl substituted with 0-3 R^{4a},~~

~~C_2-C_6 alkynyl substituted with 0-3 R^{4a},~~

~~C_3-C_{10} cycloalkyl substituted with 0-4 R^{4b},~~

~~C_3-C_{10} carbocycle substituted with 0-4 R^{4b},~~

~~aryl substituted with 0-5 R^{4b},~~

aryl-C_1-C_4-alkyl substituted with 0-5 R^{4b}; and

5-10-membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4b};

R^{4a} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3,

=O, OH, CO_2H, $C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$,

$NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$,

$S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, $NHC(=NH)NHR^{11}$,

$C(=NH)NHR^{11}$, $=NOR^{11}$, $NR^{11}C(=O)OR^{11a}$,

$NR^{11}C(=O)NR^{11}R^{11a}$, $NR^{11}SO_2NR^{11}R^{11a}$, $NR^{11}SO_2R^{11a}$,

$OP(O)(OR^{11})_2$;

C_1-C_4-alkyl substituted with 0-3 R^{4b};

C_2-C_4-alkenyl substituted with 0-3 R^{4b};

C_2-C_4-alkynyl substituted with 0-3 R^{4b};

C_3-C_7-cycloalkyl substituted with 0-4 R^{4c};

C_3-C_{10}-carbocycle substituted with 0-4 R^{4c};

aryl substituted with 0-5 R^{4c}; and

5-10-membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4c};

R^{4b} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H,
$C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$,
$NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$,
$S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, $NHC(=NH)NHR^{11}$,
$C(=NH)NHR^{11}$, $=NOR^{11}$, $NR^{11}C(=O)OR^{11a}$,
$OC(=O)NR^{11}R^{11a}$, $NR^{11}C(=O)NR^{11}R^{11a}$, $NR^{11}SO_2NR^{11}R^{11a}$,
$NR^{11}SO_2R^{11a}$, $OP(O)(OR^{11})_2$,
C_1-C_4-alkyl substituted with 0-3 R^{4e},
C_2-C_4-alkenyl substituted with 0-3 R^{4e},
C_2-C_4-alkynyl substituted with 0-3 R^{4e},
C_3-C_6-cycloalkyl substituted with 0-4 R^{4d},
aryl substituted with 0-5 R^{4d}, and
5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4d};

R^{4e} is, at each occurrence, independently selected from:
H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H,
$C(=NH)NH_2$, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$,
$NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$,
$S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$,
C_1-C_4-haloalkyl, C_1-C_4-haloalkoxy,
C_1-C_4-alkyl substituted with 0-3 R^{4d},
C_2-C_4-alkenyl substituted with 0-3 R^{4d},
C_2-C_4-alkynyl substituted with 0-3 R^{4d},
C_3-C_6-cycloalkyl substituted with 0-4 R^{4d},

aryl substituted with 0-5 R^{4d}; and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R^{4d};

R^{4d} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, NO_2, CN, NCS, CF_3, OCF_3, =O, OH, CO_2H, CO_2R^{11}, $C(=O)NR^{11}R^{11a}$, $NHC(=O)R^{11}$, $NR^{11}R^{11a}$, OR^{11a}, SR^{11a}, $C(=O)R^{11a}$, $S(=O)R^{11a}$, SO_2R^{11}, $SO_2NR^{11}R^{11a}$, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, phenyl, and benzyl;

R^8 is H or C_1-C_4 alkyl;

R^{9a} is selected from the group: H, $S(=O)R^{9b}$, $S(=O)_2R^{9b}$, $S(=O)_2NHR^{9b}$, $C(=O)R^{9b}$, $C(=O)OR^{9b}$, $C(=O)NHR^{9b}$, $C(=O)NHC(=O)R^{9b}$;

C_1-C_6 alkyl substituted with 0-3 R^{9c};

C_2-C_6 alkenyl substituted with 0-3 R^{9c};

C_2-C_6 alkynyl substituted with 0-3 R^{9c};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9d};

C_3-C_{14} carbocycle substituted with 0-4 R^{9d};

aryl substituted with 0-5 R^{9d}; and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated;

and said 5-10 membered heterocyclic group is substituted with 0-4 R^{9d};

R^{9b} is selected from the group: H;

C_1-C_6 alkyl substituted with 0-3 R^{9e};

C_2-C_6 alkenyl substituted with 0-3 R^{9e};

C_2-C_6 alkynyl substituted with 0-3 R^{9e};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9d};

C_3-C_{14} carbocycle substituted with 0-4 R^{9d};

aryl substituted with 0-5 R^{9d}; and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 R^{9d};

R^{9e} is selected from the group: CF_3, OCF_3, Cl, F, Br, I, =O, OH, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, CN, NO_2;

C_1-C_6 alkyl substituted with 0-3 R^{9d};

C_2-C_6 alkenyl substituted with 0-3 R^{9d};

C_2-C_6 alkynyl substituted with 0-3 R^{9d};

C_3-C_6 cycloalkyl substituted with 0-3 R^{9e};

C_3-C_{14} carbocycle substituted with 0-4 R^{9e};

aryl substituted with 0-5 R^{9e}; and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated;

and said 5-10-membered heterocyclic group is substituted with 0-4 R^{9e};

R^{9d} is selected at each occurrence from the group:

CF_3, OCF_3, Cl, F, Br, I, =O, OH, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, CN, NO_2;

C_1-C_4-alkyl substituted with 0-3 R^{9e};

C_1-C_4-alkoxy substituted with 0-3 R^{9e};

C_3-C_6-cycloalkyl substituted with 0-3 R^{9e};

aryl substituted with 0-5 R^{9e}; and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4 R^{9e};

R^{9e} is selected at each occurrence from the group:

C_1-C_4-alkyl, C_1-C_4-alkoxy, CF_3, OCF_3, Cl, F, Br, I, =O, OH, phenyl, $C(O)OR^{11}$, NH_2, $NH(CH_3)$, $N(CH_3)_2$, CN, and NO_2;

R^{10} is selected from the group: CO_2R^{11}, $NR^{11}R^{11a}$, and C_1-C_6 alkyl substituted with 0-1 R^{10a};

R^{10a} is selected from the group: halo, NO_2, CN, CF_3, CO_2R^{11}, $NR^{11}R^{11a}$, OR^{11}, SR^{11}, $C(=NH)NH_2$, and aryl substituted with 0-1 R^{10b};

R^{10b} is selected from the group: $-CO_2H$, $-NH_2$, -OH, -SH, and $-C(=NH)NH_2$;

R^{10c} is H or C_1-C_4 alkyl;

alternatively, R^{10} and R^{10c} can be combined to form a C_3-C_6 cycloalkyl group substituted with 0-1 R^{10a};

R^{11} and R^{11a} are, at each occurrence, independently selected from the group: H,

C_1-C_6 alkyl substituted with 0-3 R^{11b},

C_2-C_6 alkenyl substituted with 0-3 R^{11b},

C_2-C_6 alkynyl substituted with 0-3 R^{11b},

C_3-C_7 cycloalkyl substituted with 0-3 R^{11b},

aryl substituted with 0-3 R^{11b}, and

aryl(C_1-C_4 alkyl)- substituted with 0-3 R^{11b},

R^{11b} is OH, C_1-C_4 alkoxy, F, Cl, Br, I, NH_2, or $NH(C_1$-C_4 alkyl);

R^{12} is H or C_1-C_4 alkyl;

R^{14} is C_1-C_4 alkyl or C_2-C_4 alkenyl;

R^{19} and R^{19a} are independently selected from the group: H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, aryl(C_1-C_4 alkyl), C_3-C_6 cycloalkyl, and C_3-C_6 cycloalkyl(C_1-C_4 alkyl);

~~alternatively, $NR^{19}R^{19a}$ may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;~~

and

OR^{26} and OR^{27} ~~are independently selected from:~~

~~a) OH,~~

~~b) F,~~

~~c) $NR^{28}R^{29}$,~~

~~d) C_1-C_8 alkoxy, and~~

when taken together, ~~OR^{26} and OR^{27}~~ form:

~~c) a cyclic boronic ester where said cyclic boronic ester contains from 2 to 20 carbon atoms, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O~~ pinanediol.~~,~~

~~R^{28} and R^{29}, are independently selected from: H, C_1-C_4 alkyl, aryl(C_1-C_4 alkyl) , and C_3-C_7 cycloalkyl;~~

~~A^3, A^4, A^5, and A^6, are independently selected from an amino acid residue; and~~

~~an amino acid residue, at each occurence, independently comprises a natural amino acid, a modified amino acid or an unnatural amino acid wherein said natural, modified or unnatural amino acid is of either D or L configuration.~~

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (currently amended) A compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt form ~~or prodrug~~ thereof, selected from~~:~~ the group consisting of

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-3-methyl-2-[(phenylacetyl)-amino]-butanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

tert-butyl (1*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(anilinocarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-2-{[(4-

methoxyphenyl)acetyl]amino}-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9*H*-fluoren-9-ylmethyl (1*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-3-methyl-2-{[3-(trifluoromethyl)benzyl]amino)butanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[([1,1'-biphenyl]-4-ylmethyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9*H*-fluoren-9-ylmethyl (1*S*)-1-({(5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-[(2-phenyl-4-quinolinyl)methyl]imidazolidinyl}carbonyl)-2-methylpropylcarbamate;

N-((1*S*)-1-{[(5*S*)-5-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropyl)-2-chloronicotinamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(4-butylbenzoyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

isobutyl (1*S*)-1-{[(5*S*)-5-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-((2*S*)-2-{[(benzoylamino)carbonyl]amino}-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-3-methyl-2-(1-naphthoylamino)butanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-2-(acetylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-2-(benzoylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

benzyl (5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}amino)carbonyl]-2-oxo-3-[(2*E*)-3-phenyl-2-propenyl]-1-imidazolidinecarboxylate; and

benzyl (5*S*)-5-[({(1*R*)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}amino)carbonyl]-3-(2-anilino-2-oxoethyl)-2-oxo-1-imidazolidinecarboxylate.

8

~~7~~. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt form ~~or prodrug~~ thereof.

Rule 1.126 RA 9/23/03

9

~~8~~. (canceled)

10

~~9~~. (canceled)

11

~~10~~. (canceled)

12

~~11~~. (canceled)

13

~~12~~. (canceled)

14 ~~13~~. (canceled)

15 ~~14~~. (previously canceled)

16 ~~15~~. (previously canceled)

17 ~~16~~. (previously canceled)

Rule 1.126
RA 9/23/03

18 ~~17~~. (previously canceled)

19 ~~18~~. (previously canceled)

20 ~~19~~. (previously canceled)

21 ~~20~~. (previously canceled)

22 ~~21~~. (previously canceled)